## First-Line csDMARD in Early RA **Key Point:** Methotrexate is the anchor drug and gold standard first-line DMARD for all patients with RA, regardless of serology (seropositive or seronegative). **High-Yield:** ACR and EULAR guidelines recommend starting methotrexate monotherapy in all newly diagnosed RA patients within 3 months of symptom onset, irrespective of RF or anti-CCP status. ### Methotrexate as First-Line DMARD | Criterion | Methotrexate | Leflunomide | Sulfasalazine | |-----------|--------------|-------------|---------------| | **Efficacy in RA** | Excellent (60–70% remission) | Good (50–60% remission) | Moderate (40–50% remission) | | **Onset of action** | 6–12 weeks | 8–12 weeks | 6–12 weeks | | **Reversibility** | Yes (short half-life) | No (long half-life, washout needed) | Yes | | **Pregnancy safety** | Teratogenic (avoid) | Teratogenic (avoid) | Safer in pregnancy | | **Monitoring** | CBC, LFTs, renal function | CBC, LFTs | CBC, LFTs | | **First-line status** | **YES** | Second-line | Second-line | **Clinical Pearl:** Methotrexate is typically started at 10–15 mg/week (oral or SC) and titrated to 20–25 mg/week. Folic acid 5 mg daily (except on methotrexate day) reduces toxicity. Response is expected by 8–12 weeks. **Mnemonic: MTX is the Anchor** — Methotrexate is the backbone of RA therapy; all other DMARDs are added to it, not instead of it. ### Why Not Biologics First? **Warning:** Biologic TNF-α inhibitors are NOT first-line monotherapy in newly diagnosed RA. They are reserved for: - Inadequate response to csDMARD monotherapy (after 3–6 months) - High-risk disease (high disease activity + poor prognostic factors: RF+, anti-CCP+, early erosions) - In some cases, combination with methotrexate from the start in high-risk seropositive disease Using biologics as initial monotherapy is costly, unnecessary, and not guideline-recommended for standard-risk patients.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.